Drugs / Ex-vivo expanded allogeneic γδT cells
Ex-vivo expanded allogeneic γδT cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07126782 | Jul 2025 → Dec 2027 expected | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 0 | NCT04696705 | Dec 2020 → Dec 2021 | non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| Phase 0 | NCT04518774 | Aug 2020 → Jun 2021 | hepatocellular carcinoma | Beijing 302 Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05400603 | Nov 2023 → Dec 2026 expected | neuroblastoma, osteosarcoma | Emory University | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06212388 Background | Jan 2024 → Oct 2027 expected | melanoma | Xijing Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ex-vivo expanded allogeneic γδ T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06212388 ↗ |
| Modality | Cell therapy | “The ex-vivo expanded γδT cells from donors will be adoptively transfused.” NCT04518774 ↗ |
| Route | Other | “The ex-vivo expanded γδT cells from donors will be adoptively transfused.” NCT04518774 ↗ |